title: [Psoriatic arthritis: what the dermatologist needs to know, Part 2].
authors.affiliation: Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, España. alopezfe@santpau.cat
authors.forename: A
authors.initials: A
authors.lastname: López-Ferrer
authors.forename: V
authors.initials: V
authors.lastname: Torrente-Segarra
authors.forename: L
authors.initials: L
authors.lastname: Puig
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000175:diagnosis / Q000188:drug therapy / Q000523:psychology; D002986:Clinical Trials as Topic; D003880:Dermatology; D003952:Diagnostic Imaging; D018450:Disease Progression; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D012008:Recurrence; D012074:Remission Induction; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha
vernacular_title: Artritis psoriásica. Lo que el dermatólogo debe saber (Parte 2).